IMUX

Immunic

Last Updated:

Q3'20

Price

quotes and stock data delayed 15 minutes

Cash

$133.2M

Burn Rate (Qtr)

-$12.9M

Company Profile

Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn’s disease, and psoriasis.

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

IMU-838 (vidofludimus calcium) | CALVID-1

COVID-19

Phase 2 (Top-line Data)

H2 2020

IMU-838

Primary Sclerosing Cholangitis

Phase 2

2021

IMU-838

Ulcerative colitis

Phase 2

TBD

IMU-838

Multiple Sclerosis

Phase 2 Data

TBD

Recent Posts

See what the community is saying - click to see full post

IMUX - Announces Results From Interim Safety Analysis From Its Ongoing Phase 2 CALVID-1 Trial of IMU-838 in P

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon